March 19, 2008 - GlobeImmune, Inc. announced the initiation of a Phase 2a clinical trial at Memorial Sloan Kettering Cancer Center (MSKCC) to evaluate GlobeImmune’s GI-4000 Tarmogen® for the treatment of non-small cell lung cancer (NSCLC) patients with tumors having mutations in the ras gene.Molecular profiling of NSCLC tumors :
“NSCLC patients with tumors positive for mutated ras have a worse survival compared to patients with other NSCLC types in the setting of traditional therapy," said Dr. Christopher G. Azzoli, Principal Investigator for the Phase 2a study at MSKCC. "Furthermore, these patients may not benefit from treatment with selective tyrosine kinase inhibitors. Better treatments for lung cancer with mutated ras are greatly needed... GlobeImmune's Press Release -
